Transaction DateRecipientSharesTypePriceValue
11th November 2020Kevin C Oboyle16,306Disposition due to a tender of shares in a change of control transaction$30.75$501,409.50
11th November 2020Elizabeth H Weatherman38,084Disposition due to a tender of shares in a change of control transaction$30.75$1,171,083.00
10th November 2020Niamh Louise Pellegrini750Open or private sale$170.75$128,062.50
10th November 2020Niamh Louise Pellegrini750Exercise of derivative$64.95$48,712.50
1st November 2020Kashif Rashid2,192Payment by withholding$149.21$327,068.32
22nd October 2020Niamh Louise Pellegrini1,817Open or private sale$165.00$299,805.00
19th October 2020Niamh Louise Pellegrini1,000Open or private sale$155.00$155,000.00
14th October 2020Elizabeth H Weatherman500Grant/award etc.$29.95$14,975.00
13th October 2020Niamh Louise Pellegrini750Exercise of derivative$64.95$48,712.50
13th October 2020Niamh Louise Pellegrini750Open or private sale$151.47$113,602.50
Nevro
Nevro logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain.


Ticker: NVRO
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1444380
Employees: 853
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $277 M (322%)
Inventory, Net: $92 M (0%)
Assets, Current: $717 M (69%)
Property, Plant and Equipment, Net: $11 M (0%)
Other Assets, Noncurrent: $4 M (-70%)
Assets: $753 M (60%)
Accounts Payable, Current: $19 M (16%)
Accrued Liabilities, Current: $34 M (0%)
Liabilities, Current: $221 M (212%)
Long-term Debt, Excluding Current Maturities: $137 M (-14%)
Other Liabilities, Noncurrent: $2 M (3%)
Liabilities: $379 M (49%)
Common Stock, Value, Issued: $34 Th (6%)
Common Stock, Shares, Issued: $34 M (8%)
Additional Paid in Capital, Common Stock: $851 M (35%)
Retained Earnings (Accumulated Deficit): $476 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $556 Th (77%)
Stockholders' Equity (Parent): $374 M (0%)
Liabilities and Equity: $753 M (60%)
Revenue: $56 M (-60%)
Cost of Revenue: $21 M (-56%)
Gross Margin: $35 M (-63%)
Research and Development: $10 M (-53%)
Operating Income/Loss: $35 M (-39%)
Provision for income taxes: $44 Th (-87%)